Evidence map›Paper›PMID 38836230›Full record

ArticleFrontiers in endocrinology2024

Efficacy and safety of advanced hybrid closed loop systems in children with type 1 diabetes younger than 6 years.

Novella Rapini, Mariangela Martino, Claudia Arnaldi, Annalisa Deodati, Lilian Anagnostopoulou, Maria Elisa Amodeo, Paolo Ciampalini, Valentina Pampanini, Antonella Lorubbio, Davide Tosini and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Novella RapiniEndocrinology and Diabetes Unit, Bambino Gesù Children's Hospital, IRCCS, Scientific Institute for Research, Hospitalization and Health Care, Rome, Italy.
Mariangela MartinoEndocrinology and Diabetes Unit, Bambino Gesù Children's Hospital, IRCCS, Scientific Institute for Research, Hospitalization and Health Care, Rome, Italy.
Claudia ArnaldiPediatric Diabetes Unit, ASL Viterbo, Viterbo, Italy.
Annalisa DeodatiEndocrinology and Diabetes Unit, Bambino Gesù Children's Hospital, IRCCS, Scientific Institute for Research, Hospitalization and Health Care, Rome, Italy.
Lilian AnagnostopoulouEndocrinology and Diabetes Unit, Bambino Gesù Children's Hospital, IRCCS, Scientific Institute for Research, Hospitalization and Health Care, Rome, Italy.
Maria Elisa AmodeoEndocrinology and Diabetes Unit, Bambino Gesù Children's Hospital, IRCCS, Scientific Institute for Research, Hospitalization and Health Care, Rome, Italy.
Paolo CiampaliniEndocrinology and Diabetes Unit, Bambino Gesù Children's Hospital, IRCCS, Scientific Institute for Research, Hospitalization and Health Care, Rome, Italy.
Valentina PampaniniEndocrinology and Diabetes Unit, Bambino Gesù Children's Hospital, IRCCS, Scientific Institute for Research, Hospitalization and Health Care, Rome, Italy.
Antonella LorubbioEndocrinology and Diabetes Unit, Bambino Gesù Children's Hospital, IRCCS, Scientific Institute for Research, Hospitalization and Health Care, Rome, Italy.
Davide TosiniPediatric Diabetes Unit, ASL Viterbo, Viterbo, Italy.
Stefano CianfaraniEndocrinology and Diabetes Unit, Bambino Gesù Children's Hospital, IRCCS, Scientific Institute for Research, Hospitalization and Health Care, Rome, Italy.
Riccardo SchiaffiniEndocrinology and Diabetes Unit, Bambino Gesù Children's Hospital, IRCCS, Scientific Institute for Research, Hospitalization and Health Care, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tight glycemic control is essential for the normal growth and development of preschool children. The aim of our study was to evaluate the impact of advanced hybrid closed loop (AHCL) systems in a real-life setting in children younger than 6 years. Methods: We conducted a two-center prospective study. We enrolled 19 patients with a median age at disease onset of 2.6 years [interquartile range (IQR) 1.6; 4.4] and a median disease duration of 1.4 years (IQR 0.9; 2.8) who were switched to AHCL from multiple daily injections or open-loop insulin therapy and with a 6-month follow-up. Clinical data, sensor glycemic metrics, and pump settings were collected and analyzed. Results: After 6 months of follow-up, there was a significant reduction in median HbA1c ( Conclusion: AHCL systems are effective and safe for children younger than 6 years and should be considered as a valid therapeutic option from diabetes onset.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 1Hypoglycemic AgentsInsulinInsulin Infusion SystemsBlood Glucose Self-MonitoringChildChild, PreschoolFemaleFollow-Up StudiesGlycated HemoglobinGlycemic ControlHumansHypoglycemiaInfantMaleBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinAHCLchildrenCSII (continuous subcutaneous insulin infusion)insulinT1D (type 1 diabetes)

Identifiers

PMID38836230
PMCPMC11148265

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.